Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology

Marco Guazzi, Matthias Wilhelm, Martin Halle, Emeline Van Craenenbroeck, Hareld Kemps, Rudolph A de Boer, Andrew J S Coats, Lars Lund, Donna Mancini, Barry Borlaug, Gerasimos Filippatos, Burkert Pieske, Marco Guazzi, Matthias Wilhelm, Martin Halle, Emeline Van Craenenbroeck, Hareld Kemps, Rudolph A de Boer, Andrew J S Coats, Lars Lund, Donna Mancini, Barry Borlaug, Gerasimos Filippatos, Burkert Pieske

Abstract

Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as extracardiac components play a role for the limited exercise capacity, including an impaired cardiac and peripheral vascular reserve, a limitation in mechanical ventilation and/or gas exchange with reduced pulmonary vascular reserve, skeletal muscle dysfunction and iron deficiency/anaemia. Although most of these components can be differentiated and quantified through gas exchange analysis by cardiopulmonary exercise testing (CPET), the information provided by objective measures of exercise performance has not been systematically considered in the recent algorithms/scores for HFpEF diagnosis, by neither European nor US groups. The current clinical consensus statement by the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC) aims at outlining the role of exercise testing and its pathophysiological, clinical and prognostic insights, addressing the implications of a thorough functional evaluation from the diagnostic algorithm to the pathophysiology and treatment perspectives of HFpEF. Along with these goals, we provide a specific analysis of the evidence that CPET is the standard for assessing, quantifying, and differentiating the origin of dyspnoea and exercise impairment and even more so when combined with echocardiography and/or invasive haemodynamic evaluation. This will lead to improved quality of diagnosis when applying the proposed scores and may also help to implement the progressive characterization of the specific HFpEF phenotypes, a critical step toward the delivery of phenotype-specific treatments.

Keywords: Exercise; Functional limitation; Gas exchange analysis; HFpEF.

© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Figures

Figure 1
Figure 1
Plot of the Fick principle relating cardiac output to artero‐venous oxygen (a–vO2) difference and isoplets curves of oxygen uptake (VO2). The graph describes the expected relationship of heart failure with normal control pattern along with chronic obstructive pulmonary disease (COPD) and anaemia conditions as the most common comorbidities that affect oxygen (O2) content and delivery and may add on heart failure with preserved ejection fraction (HFpEF) haemodynamic, i.e. cardiac output, limitation. VT, ventilatory threshold.
Figure 2
Figure 2
The oxygen (O2) cascade during exercise. The organ systems and pathways (from air to mitochondria) involved in exercise performance are depicted along with the limiting steps and pathophysiology behind exercise limitation in heart failure with preserved ejection fraction (HFpEF). EOV, exercise oscillatory ventilation; LA, left atrial; RV, right ventricular.
Figure 3
Figure 3
Cascade of the cardiac, haemodynamic and pulmonary maladaptive response under the effects of pulmonary capillary wedge pressure (PCWP) increase. DLco, exercise diffusing lung capacity for carbon monoxide; Dm, membrane diffusion; LVEDP, left ventricular end‐diastolic pressure; Pc, pulmonary circulation; RV, right ventricular; Vc, capillary volume; VD/VT, dead space to tidal volume ratio; VE, minute ventilation; VE/VCO2, minute ventilation to carbon dioxide output. V/Q, ventilation/perfusion
Figure 4
Figure 4
Continuous of mechanisms involved in right ventricular maladaptive response to increased load and pulmonary vascular disease, affecting cardiac output and exercise performance in heart failure with preserved ejection fraction. TR, tricuspid regurgitation.
Figure 5
Figure 5
Nine‐plot analysis (A–I) of a typical cardiopulmonary exercise test response of an old hypertensive female patient with exertional dyspnoea. See text for explanation. HR, heart rate; PetCO2, end‐tidal carbon dioxide tension; PetO2, end‐tidal oxygen tension; VCO2, carbon dioxide output; VE, minute ventilation; VE/VCO2, minute ventilation to carbon dioxide output; VO2, oxygen uptake; VT, ventilatory threshold.
Figure 6
Figure 6
Nine‐plot analysis of a middle aged man with initial exertional dyspnoea presenting with a different cardiopulmonary exercise test phenotype. See text for explanation. HF, heart frequency; HR, heart rate; PetCO2, end‐tidal carbon dioxide tension; PetO2, end‐tidal oxygen tension; VCO2, carbon dioxide ouput; VE, minute ventilation; VO2, oxygen uptake; VT, ventilatory threshold.
Figure 7
Figure 7
Cardiopulmonary exercise test imaging rest to peak exercise analysis of the same case as Figure 5. Measures obtained by stress echocardiography (rest to peak exercise). The analysis was performed analysing the diastolic (E/e') and systolic (three‐dimensional longitudinal and circumferential strain) left ventricular (LV) function; the adaptive left atrial (LA) dynamics by LA strain (LAS); right ventricular (RV) function (RV ejection fraction 3D analysis) and its coupling with the pulmonary circulation by the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/PASP) ratio. Data are reported at rest (white) and at peak exercise (orange) with the changes occurring in the main variables from rest to peak. TR, tricuspid regurgitation.

References

    1. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA‐PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297–317.
    1. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence‐based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–70.
    1. Verbrugge FH, Omote K, Reddy YNV, Sorimachi H, Obokata M, Borlaug BA. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J. 2022;43:1941–51.
    1. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON‐HF trial. Circ Heart Fail. 2018;11:e004962.
    1. Houstis NE, Eisman AS, Pappagianopoulos PP, Wooster L, Bailey CS, Wagner PD, et al. Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis. Circulation. 2018;137:148–61.
    1. Guazzi M, Bandera F, Ozemek C, Systrom D, Arena R. Cardiopulmonary exercise testing: what is its value? J Am Coll Cardiol. 2017;70:1618–36.
    1. Eckhardt CM, Balte PP, Barr RG, Bertoni AG, Bhatt SP, Cuttica M, et al. Lung function impairment and risk of incident heart failure: the NHLBI pooled cohorts study. Eur Heart J. 2022;43:2196–208.
    1. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–93.
    1. Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8:172–84.
    1. Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, et al. Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. J Am Heart Assoc. 2021;10:e021494.
    1. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267–74.
    1. Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild‐type transthyretin cardiac amyloidosis. Am J Cardiol. 2019;124:122–30.
    1. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank‐Starling mechanism. J Am Coll Cardiol. 1991;17:1065–72.
    1. Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:776–85.
    1. Sarma S, Howden E, Lawley J, Samels M, Levine BD. Central command and the regulation of exercise heart rate response in heart failure with preserved ejection fraction. Circulation. 2021;143:783–9.
    1. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845–54.
    1. Sugimoto T, Bandera F, Generati G, Alfonzetti E, Bussadori C, Guazzi M. Left atrial function dynamics during exercise in heart failure: pathophysiological implications on the right heart and exercise ventilation inefficiency. JACC Cardiovasc Imaging. 2017;10:1253–64.
    1. Reddy YNV, Obokata M, Verbrugge FH, Lin G, Borlaug BA. Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol. 2020;76:1051–64.
    1. Tamargo M, Obokata M, Reddy YNV, Pislaru SV, Lin G, Egbe AC, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22:489–98.
    1. Ahmad A, Corban MT, Toya T, Verbrugge FH, Sara JD, Lerman LO, et al. Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:765–72.
    1. Obokata M, Reddy YNV, Melenovsky V, Kane GC, Olson TP, Jarolim P, et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2018;72:29–40.
    1. Parasuraman SK, Loudon BL, Lowery C, Cameron D, Singh S, Schwarz K, et al. Diastolic ventricular interaction in heart failure with preserved ejection fraction. J Am Heart Assoc. 2019;8:e010114.
    1. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.
    1. Fermoyle CC, Stewart GM, Borlaug BA, Johnson BD. Simultaneous measurement of lung diffusing capacity and pulmonary hemodynamics reveals exertional alveolar‐capillary dysfunction in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10:e019950.
    1. Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, et al. Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2017;70:136–48.
    1. Weavil JC, Thurston TS, Hureau TJ, Gifford JR, Kithas PA, Broxterman RM, et al. Heart failure with preserved ejection fraction diminishes peripheral hemodynamics and accelerates exercise‐induced neuromuscular fatigue. Am J Physiol Heart Circ Physiol. 2021;320:H338–51.
    1. Martens P, Claessen G, Van De Bruaene A, Verbrugge FH, Herbots L, Dendale P, et al. Iron deficiency is associated with impaired biventricular reserve and reduced exercise capacity in patients with unexplained dyspnea. J Card Fail. 2021;27:766–76.
    1. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 Focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2018;39:1144–61.
    1. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8:286–94.
    1. Ho JE, Zern EK, Wooster L, Bailey CS, Cunningham T, Eisman AS, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation. 2019;140:353–65.
    1. Haykowsky MJ, Nicklas BJ, Brubaker PH, Hundley WG, Brinkley TE, Upadhya B, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6:640–9.
    1. Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18:400–23.
    1. Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered hemodynamics and end‐organ damage in heart failure: impact on the lung and kidney. Circulation. 2020;142:998–1012.
    1. Roberto S, Mulliri G, Milia R, Solinas R, Pinna V, Sainas G, et al. Hemodynamic response to muscle reflex is abnormal in patients with heart failure with preserved ejection fraction. J Appl Physiol (1985). 2017;122:376–85.
    1. Pandey A, Shah SJ, Butler J, Kellogg DL Jr, Lewis GD, Forman DE, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2021;78:1166–87.
    1. Soetkamp D, Gallet R, Parker SJ, Holewinski R, Venkatraman V, Peck K, et al. Myofilament phosphorylation in stem cell treated diastolic heart failure. Circ Res. 2021;129:1125–40.
    1. Burrage MK, Hundertmark M, Valkovic L, Watson WD, Rayner J, Sabharwal N, et al. Energetic basis for exercise‐induced pulmonary congestion in heart failure with preserved ejection fraction. Circulation. 2021;144:1664–78.
    1. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–95.
    1. Wilkoff BL, Miller RE. Exercise testing for chronotropic assessment. Cardiol Clin. 1992;10:705–17.
    1. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation. 2011;123:1010–20.
    1. Palau P, Seller J, Dominguez E, Sastre C, Ramon JM, de La Espriella R, et al. Effect of beta‐blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021;78:2042–56.
    1. Mesquita T, Zhang R, Cho JH, Zhang R, Lin YN, Sanchez L, et al. Mechanisms of sinoatrial node dysfunction in heart failure with preserved ejection fraction. Circulation. 2022;145:45–60.
    1. Singleton MJ, Nelson MB, Samuel TJ, Kitzman DW, Brubaker P, Haykowsky MJ, et al. Left atrial stiffness index independently predicts exercise intolerance and quality of life in older, obese patients with heart failure with preserved ejection fraction. J Card Fail. 2021;28:567–75.
    1. Telles F, Nanayakkara S, Evans S, Patel HC, Mariani JA, Vizi D, et al. Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21:495–505.
    1. Sugimoto T, Barletta M, Bandera F, Generati G, Alfonzetti E, Rovida M, et al. Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging. Eur J Heart Fail. 2020;22:1186–98.
    1. Pandey A, Vaduganathan M, Arora S, Qamar A, Mentz RJ, Shah SJ, et al. Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance. Circulation. 2020;142:230–43.
    1. Kitzman DW, Haykowsky MJ, Tomczak CR. Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction. Circ Heart Fail. 2017;10:e004281.
    1. Chirinos JA, Segers P, Hughes T, Townsend R. Large‐artery stiffness in health and disease: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2019;74:1237–63.
    1. Namasivayam M, Lau ES, Zern EK, Schoenike MW, Hardin KM, Sbarbaro JA, et al. Exercise blood pressure in heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2022;10:278–86.
    1. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol. 2012;302:H1050–63.
    1. Sorimachi H, Burkhoff D, Verbrugge FH, Omote K, Obokata M, Reddy YNV, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:1648–58.
    1. Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week. J Am Coll Cardiol. 2020;76:1102–11.
    1. Gorter TM, Obokata M, Reddy YNV, Melenovsky V, Borlaug BA. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J. 2018;39:2825–35.
    1. Guazzi M, Naeije R. Right heart phenotype in heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14:e007840.
    1. Van Iterson EH, Johnson BD, Borlaug BA, Olson TP. Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure. Eur J Heart Fail. 2017;19:1675–85.
    1. Reddy YNV, Obokata M, Wiley B, Koepp KE, Jorgenson CC, Egbe A, et al. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J. 2019;40:3721–30.
    1. Omote K, Sorimachi H, Obokata M, Reddy YNV, Verbrugge FH, Omar M, Dubrock HM, Redfield MM, Borlaug B. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J. 2022,
    1. Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2014;306:H1364–70.
    1. Molina AJ, Bharadwaj MS, Van Horn C, Nicklas BJ, Lyles MF, Eggebeen J, et al. Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance. JACC Heart Fail. 2016;4:636–45.
    1. Parcha V, Patel N, Kalra R, Bhargava A, Prabhu SD, Arora G, et al. Clinical, demographic, and imaging correlates of anemia in heart failure with preserved ejection fraction (from the RELAX trial). Am J Cardiol. 2020;125:1870–8.
    1. Barandiaran Aizpurua A, Sanders‐van Wijk S, Brunner‐La Rocca HP, Henkens M, Weerts J, Spanjers MHA, et al. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8:1304–13.
    1. Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid‐range and preserved ejection fraction. Acta Cardiol. 2018;73:115–23.
    1. Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:657–66.
    1. Rayner JJ, Peterzan MA, Watson WD, Clarke WT, Neubauer S, Rodgers CT, et al. Myocardial energetics in obesity: enhanced ATP delivery through creatine kinase with blunted stress response. Circulation. 2020;141:1152–63.
    1. Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113:1211–6.
    1. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state‐of‐the‐art review from the Translational Research Committee of the Heart Failure Association‐European Society of Cardiology. Eur Heart J. 2018;39:4243–54.
    1. Wolsk E, Kaye D, Borlaug BA, Burkhoff D, Kitzman DW, Komtebedde J, et al. Resting and exercise haemodynamics in relation to six‐minute walk test in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2018;20:715–22.
    1. Zotter‐Tufaro C, Mascherbauer J, Duca F, Koell B, Aschauer S, Kammerlander AA, et al. Prognostic significance and determinants of the 6‐min walk test in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2015;3:459–66.
    1. Maldonado‐Martin S, Brubaker PH, Eggebeen J, Stewart KP, Kitzman DW. Association between 6‐minute walk test distance and objective variables of functional capacity after exercise training in elderly heart failure patients with preserved ejection fraction: a randomized exercise trial. Arch Phys Med Rehabil. 2017;98:600–3.
    1. Armstrong PW, CSP Lam, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, et al.; VITALITY‐HFpEF Study Group . Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY‐HFpEF randomized clinical trial. JAMA. 2020;324:1512–21.
    1. Shah SJ, Cowie MR, Wachter R, Szecsody P, Shi V, Ibram G, et al. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:1541–51.
    1. Guazzi M, Dickstein K, Vicenzi M, Arena R. Six‐minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail. 2009;2:549–55.
    1. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al.; EACPR and AHA . EACPR/AHA Joint Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2012;33:2917–27.
    1. Agostoni P, Dumitrescu D. How to perform and report a cardiopulmonary exercise test in patients with chronic heart failure. Int J Cardiol. 2019;288:107–13.
    1. Reddy YNV, Olson TP, Obokata M, Melenovsky V, Borlaug BA. Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6:665–75.
    1. Nayor M, Houstis NE, Namasivayam M, Rouvina J, Hardin C, Shah RV, et al. Impaired exercise tolerance in heart failure with preserved ejection fraction: quantification of multiorgan system reserve capacity. JACC Heart Fail. 2020;8:605–17.
    1. Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. Eur Respir Rev. 2021;30:200187.
    1. Boucly A, Morelot‐Panzini C, Garcia G, Weatherald J, Jais X, Savale L, et al. Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. Eur Respir J. 2020;55:1802108.
    1. Neder JA, Arbex FF, Alencar MC, O'Donnell CD, Cory J, Webb KA, et al. Exercise ventilatory inefficiency in mild to end‐stage COPD. Eur Respir J. 2015;45:377–87.
    1. Teopompi E, Tzani P, Aiello M, Gioia MR, Marangio E, Chetta A. Excess ventilation and ventilatory constraints during exercise in patients with chronic obstructive pulmonary disease. Respir Physiol Neurobiol. 2014;197:9–14.
    1. Klaassen SHC, Liu LCY, Hummel YM, Damman K, van der Meer P, Voors AA, et al. Clinical and hemodynamic correlates and prognostic value of VE/VCO2 slope in patients with heart failure with preserved ejection fraction and pulmonary hypertension. J Card Fail. 2017;23:777–82.
    1. Alenezi F, Covington TA, Mukherjee M, Mathai SC, Yu PB, Rajagopal S. Novel approaches to imaging the pulmonary vasculature and right heart. Circ Res. 2022;130:1445–65.
    1. Reddy YNV, Kaye DM, Handoko ML, Van de Bovenkamp AA, Tedford RJ, Keck C, Anderson MJ, Sharma K, Trivedi RK, Carter RE, Obokata M, Vergrubbe FH, Redfield MM, Borlaug BA. Diagnosis of heart failure with preserved ejection fraction with unexplained dyspena. JAMA Cardiol. 2022.
    1. Barron A, Francis DP, Mayet J, Ewert R, Obst A, Mason M, et al. Oxygen uptake efficiency slope and breathing reserve, not anaerobic threshold, discriminate between patients with cardiovascular disease over chronic obstructive pulmonary disease. JACC Heart Fail. 2016;4:252–61.
    1. Popovic D, Arena R, Guazzi M. A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid‐range, and preserved ejection fraction. Eur J Heart Fail. 2018;20:1115–24.
    1. Guazzi M, Dixon D, Labate V, Beussink‐Nelson L, Bandera F, Cuttica MJ, et al. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging. 2017;10:1211–21.
    1. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Exercise oscillatory breathing in diastolic heart failure: prevalence and prognostic insights. Eur Heart J. 2008;29:2751–9.
    1. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.
    1. Donal E, Lund LH, Oger E, Reynaud A, Schnell F, Persson H, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging. 2016;17:106–13.
    1. Shim CY, Kim SA, Choi D, Yang WI, Kim JM, Moon SH, et al. Clinical outcomes of exercise‐induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart. 2011;97:1417–24.
    1. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive‐echocardiographic study. Circulation. 2017;135:825–38.
    1. Obokata M, Kane GC, Sorimachi H, Reddy YNV, Olson TP, Egbe AC, et al. Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension. Eur Respir J. 2020;55:1901617.
    1. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50:1700578.
    1. Claessen G, La Gerche A, Voigt JU, Dymarkowski S, Schnell F, Petit T, et al. Accuracy of echocardiography to evaluate pulmonary vascular and RV function during exercise. JACC Cardiovasc Imaging. 2016;9:532–43.
    1. Martens P, Herbots L, Timmermans P, Verbrugge FH, Dendale P, Borlaug BA, et al. Cardiopulmonary exercise testing with echocardiography to identify mechanisms of unexplained dyspnea. J Cardiovasc Transl Res. 2021;15:116–30.
    1. Guazzi M, Borlaug B, Metra M, Losito M, Bandera F, Alfonzetti E, et al. Revisiting and implementing the weber and ventilatory functional classifications in heart failure by cardiopulmonary imaging phenotyping. J Am Heart Assoc. 2021;10:e018822.
    1. Nedeljkovic I, Banovic M, Stepanovic J, Giga V, Djordjevic‐Dikic A, Trifunovic D, et al. The combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. Eur J Prev Cardiol. 2016;23:71–7.
    1. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54:402–9.
    1. Simonovic D, Coiro S, Deljanin‐Ilic M, Kobayashi M, Carluccio E, Girerd N, et al. Exercise‐induced B‐lines in heart failure with preserved ejection fraction occur along with diastolic function worsening. ESC Heart Fail. 2021;8:5068–80.
    1. Hubert A, Girerd N, Le Breton H, Galli E, Latar I, Fournet M, et al. Diagnostic accuracy of lung ultrasound for identification of elevated left ventricular filling pressure. Int J Cardiol. 2019;281:62–8.
    1. Bandera F, Barletta M, Fontana M, Boveri S, Ghizzardi G, Alfonzetti E, et al. Exercise‐induced mitral regurgitation and right ventricle to pulmonary circulation uncoupling across the heart failure phenotypes. Am J Physiol Heart Circ Physiol. 2021;320:H642–53.
    1. Ho JE, Zern EK, Lau ES, Wooster L, Bailey CS, Cunningham T, et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort. J Am Coll Cardiol. 2020;75:17–26.
    1. Satho T, Wang L, Espinosa‐Diez C, Wang B, Hahn SA, Noda K, Rochon ER et al Metabolic syndrome mediates ROS‐miR‐193b‐NFYA‐dependent downregulation of soluble guanylate cyclase and contributes to exercise‐induced pulmonary hypertension in heart failure with preserved ejection fraction. Circulation. 2021;144:615–37.
    1. Andersen MJ, Hwang SJ, Kane GC, Melenowski V, Olson TP, Fetterly K, Borlaug BA. Enhanced pulmonary vasodilator reserve and abnormal right ventricular pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail. 2015;8:542–50.
    1. Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, et al. Pulmonary capillary wedge pressure during exercise and long‐term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3103–12.
    1. Lewis GD, Bossone E, Naeije R, Grunig E, Saggar R, Lancellotti P, et al. Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation. 2013;128:1470–9.
    1. Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158:2119–29.
    1. Nadruz W Jr, West E, Sengelov M, Santos M, Groarke JD, Forman DE, et al. Prognostic value of cardiopulmonary exercise testing in heart failure with reduced, midrange, and preserved ejection fraction. J Am Heart Assoc. 2017;6:e006000.
    1. Shafiq A, Brawner CA, Aldred HA, Lewis B, Williams CT, Tita C, et al. Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry ford HospITal CardioPulmonary EXercise testing (FIT‐CPX) project. Am Heart J. 2016;174:167–72.
    1. Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:3–15.
    1. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, et al. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail. 2018;11:e004750.
    1. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4:607–16.
    1. Takken T, Mylius CF, Paap D, Broeders W, Hulzebos HJ, Van Brussel M, et al. Reference values for cardiopulmonary exercise testing in healthy subjects – an updated systematic review. Expert Rev Cardiovasc Ther. 2019;17:413–26.
    1. Sun XG, Hansen JE, Stringer WW. Oxygen uptake efficiency plateau: physiology and reference values. Eur J Appl Physiol. 2012;112:919–28.
    1. Obokata M, Olson TP, Reddy YNV, Melenovsky V, Kane GC, Borlaug BA. Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. Eur Heart J. 2018;39:2810–21.
    1. Smith JR, Van Iterson EH, Johnson BD, Borlaug BA, Olson TP. Exercise ventilatory inefficiency in heart failure and chronic obstructive pulmonary disease. Int J Cardiol. 2019;274:232–6.
    1. Petersson J, Glenny RW. Gas exchange and ventilation‐perfusion relationships in the lung. Eur Respir J. 2014;44:1023–41.
    1. Belardinelli R, Lacalaprice F, Carle F, Minnucci A, Cianci G, Perna G, et al. Exercise‐induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J. 2003;24:1304–13.
    1. Hearon CM Jr, Sarma S, Dias KA, Hieda M, Levine BD. Impaired oxygen uptake kinetics in heart failure with preserved ejection fraction. Heart. 2019;105:1552–8.
    1. Chatterjee NA, Murphy RM, Malhotra R, Dhakal BP, Baggish AL, Pappagianopoulos PP, et al. Prolonged mean VO2 response time in systolic heart failure: an indicator of impaired right ventricular‐pulmonary vascular function. Circ Heart Fail. 2013;6:499–507.
    1. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart‐rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–7.
    1. Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. JAMA. 2020;324:1522–31.
    1. Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42:700–10.
    1. Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, et al. Levosimendan improves hemodynamics and exercise tolerance in PH‐HFpEF: results of the randomized placebo‐controlled HELP trial. JACC Heart Fail. 2021;9:360–70.
    1. Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol. 2012;60:120–8.
    1. Edelmann F, Gelbrich G, Dungen HD, Frohling S, Wachter R, Stahrenberg R, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex‐DHF (Exercise Training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780–91.
    1. Mueller S, Haller B, Halle M; OptimEx‐Clin Study Group . Effect of training on peak oxygen consumption in patients with heart failure with preserved ejection fraction‐reply. JAMA. 2021;326:772–3.
    1. Kraigher‐Krainer E, Lyass A, Massaro JM, Lee DS, Ho JE, Levy D, et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: the Framingham Heart Study. Eur J Heart Fail. 2013;15:742–6.
    1. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69:1129–42.
    1. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315:36–46.
    1. Wolsk E, Kaye D, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, et al. Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. JACC Heart Fail. 2019;7:321–32.
    1. Dalos D, Mascherbauer J, Zotter‐Tufaro C, Duca F, Kammerlander AA, Aschauer S, et al. Functional status, pulmonary artery pressure, and clinical outcomes in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:189–99.
    1. Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, et al.; OptimEx‐Clin Study Group . Effect of high‐intensity interval training, moderate continuous training, or guideline‐based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2021;325:542–51.
    1. Pandey A, Parashar A, Kumbhani DJ, Agarwal S, Garg J, Kitzman D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta‐analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40.
    1. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, et al. Dose‐response relationship between physical activity and risk of heart failure: a meta‐analysis. Circulation. 2015;132:1786–94.
    1. Hieda M, Sarma S, Hearon CM Jr, MacNamara JP, Dias KA, Samels M, et al. One‐year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction. Circulation. 2021;144:934–46.
    1. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29:230–45.
    1. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype‐specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134:73–90.
    1. Tanner FC, Brooks N, Fox KF, Gonçalves L, Kearney P, Michalis L, et al. ESC core curriculum for the cardiologist. Eur Heart J. 2020;41:3605–92.
    1. Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, et al. EACP core curriculum for preventive cardiology. Eur J Prev Cardiol. 2021;29:251–74.

Source: PubMed

3
Subskrybuj